Results 21 to 30 of about 9,825 (155)

Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. [PDF]

PLoS ONE, 2018
Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care's benefit package.
Waranya Rattanavipapong, Thunyarat Anothaisintawee, Yot Teerawattananon   +2 more
doaj   +1 more source

Photochemical Reaction Discovery Enabled by the Dynamic Speciation of Copper Complexes

Angewandte Chemie, EarlyView.
A strategy for accelerated photochemical reaction discovery is reported that harnesses the dynamic speciation of copper complexes, driven by their labile metal–ligand bonds. This platform simplifies reaction screening by combining an earth‐abundant copper(II) salt with commercially available ligands, which reversibly generate multiple catalytic species
Alessio Regni, Siyu Liang, Supreeta Sen, Hailey Hendricks, Xijue Wu, Matthew V. Pecoraro, Jose B. Roque   +6 more
wiley   +2 more sources

Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

BMC Infectious Diseases, 2019
Background Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4–5 chronic kidney disease (CKD) needs further observation in real world.
Taotao Yan, Jiuping Wang, Juan Li, Shan Fu, Yi Chen, Chunhua Hu, Rou Zhang, Zhen Tian, Fahui Zhao, Jun Dong, Jinfeng Liu, Yuan Yang, Tianyan Chen, Yingren Zhao, Yingli He   +14 more
doaj   +1 more source

Role of Direct Antiviral Agents in Treatment of Chronic Hepatitis C Infection in Renal Transplant Recipients

Journal of Transplantation, 2018
Background. Since the introduction of direct antiviral agents (DAAs), morbidity of HCV has considerably decreased but still no guidelines have been formulated in renal transplant recipients (RTRs). We studied efficacy and tolerability of direct antiviral
Sourabh Sharma, Debabrata Mukherjee, Ranjith K. Nair, Bhaskar Datt, Ananth Rao   +4 more
doaj   +1 more source

Medicament testing on acupuncture points as a non-invasive diagnostic tool for determining the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection

Future Journal of Pharmaceutical Sciences, 2023
Background Acupuncture points are known for their unique bioelectric properties. Medication testing at acupuncture points has not previously been used to determine the daily doses of sofosbuvir in patients with chronic hepatitis C virus infection ...
Naylya Djumaeva, Gulnara Akhundjanova, Leyla Djumaeva, Dilbar Urunova   +3 more
doaj   +1 more source

Sustained virological response to antiviral drugs in treatment of different genotypes of HCV cirrhotic patients

Pakistan Journal of Pharmaceutical Sciences, 2023
Cirrhosis and liver cancer are both caused by hepatitis C virus (HCV) infection of the liver. Patients with HCV cirrhosis may be treated with one of many antiviral medications, depending on their specific genotype.
Amin Ullah, Aqsa Maryam, Ghaffarul Malik, Hira Hameed, Kifayat Hussain, Junaid Ahmad, Ihteshamul Haq, Mohsina Haq, Reem M Aljowaie, Elsayed Mohsen Abougazia, Tse-Wei Chen, Jamshaid Ahmad, Kashif Bashir, Laiba Ahmad, Bashir Ahmad   +14 more
doaj   +1 more source

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea [PDF]

Clinical and Molecular Hepatology, 2015
Background/AimsThe previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions.
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim   +5 more
doaj   +1 more source

Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study

The Lancet Microbe, 2020
Summary: Background: Hepatitis C virus (HCV) infection is increasing among pregnant women because of the opioid epidemic, yet there are no interventions to reduce perinatal HCV transmission or to treat HCV during pregnancy.
Catherine A Chappell, MD, Kimberly K Scarsi, PharmD, Brian J Kirby, PhD, Vithika Suri, MSc, Anuj Gaggar, MD, Debra L Bogen, ProfMD, Ingrid S Macio, PA, Leslie A Meyn, PhD, Katherine E Bunge, MD, Elizabeth E Krans, MD, Sharon L Hillier, ProfPhD   +10 more
doaj   +1 more source

The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.

PLoS ONE, 2021
BackgroundDirect-acting antiviral (DAA) drugs have been effective in the treatment of chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and efficacy in American Indian or Alaska Native people.
Lisa Townshend-Bulson, Elena Roik, Youssef Barbour, Dana J T Bruden, Chriss E Homan, Hannah G F Espera, Timothy J Stevenson, Annette M Hewitt, Wileina Rhodes, James E Gove, Julia N Plotnik, Mary M Snowball, John McGilvray, Brenna C Simons, Janet M Johnston, Brian J McMahon   +15 more
doaj   +1 more source

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience

Infection and Drug Resistance, 2021
Qiao Tang, Li Wei, Xiaoqing Liu, Peng Hu Department of Infectious Diseases, Institute for Viral Hepatitis, The Key Laboratory of Molecular Biology for Infectious Diseases, Chinese Ministry of Education, The Second Affiliated Hospital of Chongqing Medical
Tang Q, Wei L, Liu X, Hu P
doaj